Roche has agreed to acquire cancer drug developer Ignyta for US$27 per share, equating to a total transaction value of US$1.7 B and a huge 74% premium over Ignyta’s closing stock price before the deal was announced. Ignyta’s lead compound, entrectinib, is an orally available tyrosine kinase inhibitor in development for tumours harbouring ROS1 or NRTK fusions. It was granted a Breakthrough Therapy Designation by the US FDA in 2017.